CardioScale

What CardioScale does

CardioScale Ltd. is a privately held Israeli medical device company founded in 2012 and headquartered in Ganei Tikva, Israel. The company has developed a patented multi-vital sign index called the Cardiovascular Reserve Index (CVRI) that assesses a patient's hemodynamic state and trajectory to project developing cardiovascular deterioration, including in the compensated phase when individual vital signs still appear normal. Its commercial product is the DTR8 portable arm monitor, which combines standard vital sign measurement (blood pressure, heart rate, respiratory rate, pulse oximetry, capnography) with on-device CVRI calculation, with the index also offered for licensing and integration into third-party patient monitoring systems. Target customers span hospital ICUs and emergency departments, emergency medical services and first response teams, military medical corps, and chronic disease populations such as congestive heart failure patients. The CVRI calculator received CE Mark Class IIa approval in October 2019, enabling clinical use across the European Union, and patents have been granted in the United States, China, Japan, and Australia.

The business model combines hardware sales of the DTR8 device with technology licensing of the CVRI algorithm to other medical device manufacturers, supported by an event-driven go-to-market centered on medical conferences (MEDinIsrael, ESICM, Digital.Health.Now) and direct engagement with hospitals, EMS organizations, and military medical corps. The company is small (1-10 employees) and the only disclosed capital inflow is a $100,000 grant from the 2018 CTTSC3 competition; there is no publicly disclosed pricing, sales pipeline, or commercial revenue. Leadership comprises CEO Maoz Ben-Ari (former IDF special forces major, MBA from Jiao-Tong University) and co-founders Dr. Uri Gabbay (Tel Aviv University senior lecturer and practicing physician) and Prof. Ben-Zion Bobrovsky (Tel Aviv University Emeritus Professor of Electrical Engineering), with an advisory board drawing from senior Israeli hospital and defense establishment figures.

Name

CardioScale

Legal name

CardioScale Ltd.

Website

https://cardioscale.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

CardioScale is an Israeli medical device company founded in 2012 that has developed the patented CVRI multi-vital sign index and DTR8 portable monitor for early detection of cardiovascular hemodynamic deterioration, serving hospitals, EMS, military medical corps, and chronic care patients.

Ownership category

akta.pro rank

Product category

Patient Monitoring Devices

SIC

Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)

akta.pro secondary industries

Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), Chronic Disease Management & Remote Patient Monitoring (RPM) (HSABACAD)

Keywords

• Hemodynamic monitoring devices
• Cardiovascular diagnostic devices
• Patient deterioration detection
• Medical monitoring technology
• Vital sign analysis

Headquarters

HQ city

Gat Rimon

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: Sale of DTR8 portable monitoring device and CVRI calculator hardware to hospitals, emergency medical services, military, and healthcare facilities
2. Technology Licensing: Licensing of CVRI technology for integration into third-party medical devices and monitoring systems

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

CardioScale develops and sells the patented CVRI (Cardio Vascular Reserve Index), a non-invasive multi-vital sign index that detects early cardiovascular hemodynamic deterioration in patients, along with the DTR8 portable monitor that measures vital signs and calculates the CVRI score. The technology is sold as a hardware device (DTR8) and licensed for integration into third-party medical devices and monitoring systems.

Product overview

CardioScale offers a patented CVRI (Cardio Vascular Reserve Index) technology for early detection of cardiovascular hemodynamic deterioration. The product portfolio centers on the DTR8 portable monitor device, which provides vital sign measurements (blood pressure, heart rate, respiratory rate, pulse, oxymeter, capnography) and calculates the proprietary CVRI index. CVRI can also be integrated into existing medical devices and monitoring systems. The technology enables prediction of patient deterioration even when vital signs are within normal range, serving use cases including shock, sepsis, trauma, ICU monitoring, pre/post-operation, and chronic conditions such as congestive heart failure.

Differentiator

Problem solved

Functional benefit

Products and services

• CVRI (Cardio Vascular Reserve Index) Patented hemodynamic assessment technology that predicts patient deterioration by analyzing multi-vital sign data. CVRI is a numeric index that detects hemodynamic changes from a patient's own baseline, providing directional indication of compromise or improvement even when individual vital signs are normal. Sold to hospitals, ICUs, emergency medical services, and military medical corps.
• DTR8 Portable Monitor All-in-one portable arm monitor that provides vital sign measurement (blood pressure, heart rate, respiratory rate, pulse, oxymeter, capnography) and calculates CVRI. Designed for field use by militaries, EMS, hospitals, and first response teams in scenarios including terror attacks, accidents, and disasters.

Quantifiable outcome

• 100% prediction of deterioration in IDF hemorrhage study (17 out of 17 cases)

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Israeli Defense Forces (IDF) Medical CorpscoreStrategic or Co-development Partner · 1 January 2015IDF Medical Corps performed hemorrhage swine study in 2015 testing CVRI technology among other deterioration predictors. Results showed 100% prediction of deterioration with hit rate of 17 out of 17 cases. IDF described CVRI as 'a promising potential predictive measure of hemorrhage-related hemodynamic deterioration.'
• Israeli Defense Forces (Medical Corps)coreStrategic or Co-development PartnerCooperation with IDF Medical Corps for Digital.Health.Now 2018 conference in Tel Aviv focusing on healthcare challenges and innovative solutions
• ESICM (European Society of Intensive Care Medicine)minorStrategic or Co-development PartnerCardioScale's abstract 'The cardiovascular reserve index (CVRI) - a potential indicator of hemodynamic deterioration' was selected for presentation at the Vienna Congress for Intensive Care Medicine, Sep 23-27, 2017. Abstract published in ESICM official journal Intensive Care Medicine Experimental.
• Garage+ / Epoch Foundation (Taiwan)minorStrategic or Co-development PartnerSelected to participate in Global Startup Program in Taipei, Taiwan from May 22 to June 2, 2016. Program arranged meetings with potential investors and business partners, with booths at COMPUTEX exhibition.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Deltex Medical: UK-based company that developed the CardioQ esophageal Doppler monitor for non-invasive hemodynamic monitoring. Directly comparable as a small-cap specialist in non-invasive hemodynamic assessment.
• Edwards Lifesciences: Global leader in hemodynamic monitoring, including the Swan-Ganz catheter and FloTrac/Vigileo systems. Directly comparable to CardioScale in serving hemodynamic assessment in critical care settings, though Edwards focuses predominantly on invasive monitoring in the cath lab and OR.
• Uscom: Australian developer of non-invasive hemodynamic monitoring devices (USCOM 1A) for cardiac output and cardiovascular function. Comparable niche player in non-invasive hemodynamic monitoring with patents and clinical validation.
• LiDCO Group: UK-based developer of minimally invasive and non-invasive hemodynamic monitoring technologies (LiDCOrapid, LiDCOunity) used in ICU and surgical settings. Directly comparable in technology category and customer base to CardioScale.
• Finapres Medical Systems: Dutch company specializing in non-invasive continuous hemodynamic monitoring via finger-cuff technology (Finometer, Portapres). Comparable to CardioScale's CVRI in providing non-invasive hemodynamic data for clinical decision-making.
• Cheetah Medical (Baxter): Acquired by Baxter, Cheetah Medical pioneered non-invasive hemodynamic monitoring (NICOM/Starling SV). Directly comparable to CardioScale's CVRI in offering non-invasive, real-time hemodynamic assessment for critically ill patients.

Broad incumbents

• Philips (Patient Monitoring): Global incumbent in patient monitoring (IntelliVue, IntelliVue X3) with broad ICU, EMS, and remote monitoring offerings. Represents the dominant installed base against which CardioScale's standalone CVRI solution must compete.
• GE HealthCare: Major patient monitoring and critical care solutions provider (CARESCAPE, IntelliVue competitors) with global scale, integrated EMR connectivity, and capital purchasing relationships in hospitals.
• Mindray: Chinese medical device major with extensive patient monitoring portfolio (BeneVision, ePM) competing on price-performance in both developed and emerging markets — a relevant comparator for international expansion strategy.

Emerging players

• Masimo: Non-invasive monitoring innovator (SET pulse oximetry, rainbow Pulse CO-Oximetry) with growing hemodynamic and patient status index offerings (RD SedLine, SedLine brain monitoring). Comparable as a measurement-IP-driven company expanding from single-parameter to composite indices.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CardioScale
• LinkedInlinkedin.com/company/cardioscale-ltd-

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CardioScale